OptiBiotix Health (STU:OB3) Notes Receivable: €0.00 Mil (As of Dec. 2025)


What is OptiBiotix Health Notes Receivable?

OptiBiotix Health STU:OB3 +1.39% Notes Receivable is €0.00 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

OptiBiotix Health's Notes Receivable for the quarter that ended in Dec. 2025 was €0.00 Mil.

OptiBiotix Health Notes Receivable Related Terms

OptiBiotix Health Notes Receivable Historical Data

* Premium members only.

The historical data trend for OptiBiotix Health's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OptiBiotix Health Notes Receivable Chart

OptiBiotix Health Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OptiBiotix Health Semi-Annual Data
Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OptiBiotix Health Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
OptiBiotix Health (STU:OB3) has a Notes Receivable of €0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on OptiBiotix Health and its competitors.
Is OptiBiotix Health's Notes Receivable too high?
OptiBiotix Health's current Notes Receivable is €0.00 Mil.
How does OptiBiotix Health's Notes Receivable compare to VRTX and REGN?
OptiBiotix Health's Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on OptiBiotix Health and its competitors. OptiBiotix Health's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OptiBiotix Health stock overvalued right now?
OptiBiotix Health (STU:OB3) has a current Notes Receivable of €0.00 Mil. The stock's GF Value™ is €0.34, compared to a current price of €0.07 — trading 78.5% below its estimated fair value. The current Notes Receivable is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For OptiBiotix Health (STU:OB3), the current Notes Receivable is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OptiBiotix Health Business Description

Other Exchanges OPTI:UK
Address Innovation Centre, Innovation Way, Heslington, York, GBR, YO10 5DG
OptiBiotix Health PLC principal activity is that of identifying and developing microbial strains, compounds, and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits. It is a life sciences business focused on the development of products which reduce hunger and food cravings, enhance the gut microbiome, and provide a healthy substitute for sugar. Its product portfolio includes First-generation products- SlimBiome, WellBiome; and Second-generation solutions- SweetBiotix, Microbiome Modulators. The group has one class of business. It has presence in United Kingdom, United States, India China, and Rest of world. The company generates majority of revenue from United States.